User profiles for B. Gini

Beatrice Gini, Ph.D.

University of California at San Francisco (UCSF)
Verified email at ucsf.edu
Cited by 4131

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments

K Masui, B Gini, J Wykosky, C Zanca… - …, 2013 - academic.oup.com
Chemotherapy and molecularly targeted approaches represent two very different modes of
cancer treatment and each is associated with unique benefits and limitations. Both types of …

Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA

DA Nathanson, B Gini, J Mottahedeh, K Visnyei… - Science, 2014 - science.org
Intratumoral heterogeneity contributes to cancer drug resistance, but the underlying
mechanisms are not understood. Single-cell analyses of patient-derived models and clinical …

Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis

…, B Rossi, S Angiari, L Calderan, E Anghileri, B Gini… - Stem …, 2009 - academic.oup.com
… (B) Total draining lymph node cells were isolated from mice transplanted with ASC in the
pre-clinical phase of the disease and from control mice. Ex vivo analysis of T-cell proliferation of …

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

CM Blakely, TBK Watkins, W Wu, B Gini, JJ Chabon… - Nature …, 2017 - nature.com
A widespread approach to modern cancer therapy is to identify a single oncogenic driver
gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-…

Oncogenic EGFR signaling activates an mTORC2–NF-κB pathway that promotes chemotherapy resistance

…, I Babic, D Nathanson, D Akhavan, D Guo, B Gini… - Cancer discovery, 2011 - AACR
B, immunoblot analysis of LN229 GBM cells in which EGFRvIII was placed under a
doxycycline-regulatable promoter. C, representative immunohistochemical images demonstrating p-…

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR–dependent pathway

…, S Zhu, I Babic, K Tanaka, J Dang, A Iwanami, B Gini… - Cancer discovery, 2011 - AACR
B, quantitative analysis of LDLR expression in GBM versus adjacent normal tissues. C,
correlation analysis between LDLR expression and p-EGFR, p-Akt, or SREBP-1 in 140 GBM …

[PDF][PDF] mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc

K Masui, K Tanaka, D Akhavan, I Babic, B Gini… - Cell metabolism, 2013 - cell.com
… of acetylated FoxO1 and FoxO3 (Figure 2B). Rictor knockdown also increased the formation
… Conversely, Rictor overexpression increased the level of FoxO acetylation (Figure S2B) and …

[HTML][HTML] The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

…, N I. Vokes, M Dietzen, M Angelova, B Gini… - Nature Genetics, 2024 - nature.com
… In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (… A3B
and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3B …

[HTML][HTML] Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment

…, T Imahori, Y Ejima, K Masui, B Gini… - The Journal of …, 2015 - Am Soc Clin Investig
… (B) Glutamine and glutamate levels in MRS studies for tumors and contralateral normal
brain regions in 12 GBM patients. The relative level of glutamine and glutamate was calculated …

[PDF][PDF] Single-cell phosphoproteomics resolves adaptive signaling dynamics and informs targeted combination therapy in glioblastoma

…, TF Cloughesy, PS Mischel, JR Heath, B Gini - Cancer cell, 2016 - cell.com
… In Figure 6B we plot the correlations of the assayed proteins, … constitute mode 1 of Figure
4B lie principally along PC1, as … two signaling modes (Figure 4B) resolved in the SCBC data …